Harvard Medical School Duane S. Pinto, M.D. Director Peripheral Angiographic Core Laboratory, TIMI Data Coordinating Center Director, Cardiology Fellowship.

Slides:



Advertisements
Similar presentations
Coronary MDCTA Applications
Advertisements

SLOW- COOKING THE BEANS “OR, HOW TO STOP WORRYING AND APPLY SOME LOVE TO THE KIDNEYS” AN APPROACH TO CKD SARA KATE LEVIN, MD JANUARY 2014.
Single Center Experience with Drug Eluting Stents for Infrapopliteal Occlusive Disease in Patients with Critical Limb Ischemia: Mid-term follow up Robert.
Techniques of Renal Arteriography Subhash Banerjee, MD UT Southwestern Med. Ctr & VA North Texas Health care; Dallas, TX.
CKD In Primary Care Dr Mohammed Javid.
The DRASTIC Trial. Dutch Renal Artery Stenosis Intervention Cooperative Reference van Jaarsveld BC, Krijnen P, Derkx FHM, et al. Resistance to antihypertensive.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Zehra Eren, M.D.. explain hypertansion and renal disease interaction, describe renovascular diseases describe diagnostic evaluation explan therapy in.
Renovascular Hypertension and Renal Artery Ultrasounds Amajd AlMahameed, MD, MPH Division of Cardiology Beth Israel Deaconess Medical Center Boston.
Lesley Stevens MD Tufts-New England Medical Center
IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Management of Renal Artery Stenosis Kent MacKenzie, MD Division of Vascular Surgery McGill University Montreal, Quebec.
Clinical Appraisal of an Article on Prognosis The Clinical Question Will the prognosis of patients with gout be affected by the administration allupurinol?
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
Controversies in renal arterial interventions. ACHILLES CHATZIIOANNOU, MD Assoc. Professor of Radiology American Board of Radiology.
Indication and contra-indications for cardiac catheterization
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
PREDICTING AKI IS MORE CHALLENGING AS AGE PROGRESSES Sandra Kane-Gill, PharmD, MSc Associate Professor, School of Pharmacy.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Renovascular Disease Daniel Shoskes MD, MSc, FRCSC Professor of Surgery/Urology Glickman Urological and Kidney Institute Cleveland Clinic.
Philip A Kalra Lead Nephrologist for ASTRAL, Hope Hospital, Salford, UK, On behalf of the ASTRAL TMC and collaborators UK MULTI-CENTRE TRIAL IN ATHEROSCLEROTIC.
Clinical Trial Results. org C. Michael Gibson, M.S., M.D. Director TIMI Data Coordinating Center Invasive Cardiologist Beth Israel Deaconess Medical Center.
MedPix Medical Image Database COW - Case of the Week Case Contributor: Thomas C Alewine Affiliation: National Capital Consortium.
Section 5: Configuration of healthcare to manage CKD.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Although in more than 90% of patients with high blood pressure no underlying causes could be identified, up to 10% of hypertensives have a secondary.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Renovascular hypertension Dr Saad Al Shohaib KAUH.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
بسم الله الرحمن الرحيم. RENAL ARTERY STENOSIS  Lecture by:  Dr. Zaidan Jayed Zaidan.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
BY Dr. Hayam Hebah Associate professor of Internal Medicine AL Maarefa College.
Relationship between coronary and renal artery disease and associated risk factors in hypertensive and diabetic patients undergoing coronary angiography.
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
KIDNEY & HYPERTENTION 1 Dr. Ruba Nashawati. Kidney Hypertension 2.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Prognosis of Acute Kidney Injury After.
The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Uncertain Value of Renal Artery Interventions:
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
Renal vascular disease
Renovascular Disease Daniel Shoskes MD, MSc, FRCSC
Behandeling van laag-gradige nierarteriestenosen PROTAGORAS studie
Renovascular Hypertension
Renal Artery Angioplasty and Stenting: Optimal Patient Selection
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
TECHNINIQUES OF RENAL ARTERY STENTING
TUCOM Internal Medicine 4th class
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
Renal Artery Angioplasty and Stenting
Techniques of Renal Arteriography
Patient Selection Indications for Renal Intervention
Renal CTA: Can We Determine Who Will Benefit from RAS
Fractional Flow Reserve Workshop
RAAS Blockade: Focus on ACEI
Progress and Promise in RAAS Blockade
The Hypertension in the Very Elderly Trial (HYVET)
These slides highlight a report from a presentation at the European Society of Cardiology 2003 Congress in Vienna Austria, August 30 - September 3, 2003.
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
Correlation between endothelial function and hypertension
American Journal of Kidney Diseases
Presentation transcript:

Harvard Medical School Duane S. Pinto, M.D. Director Peripheral Angiographic Core Laboratory, TIMI Data Coordinating Center Director, Cardiology Fellowship Training Program Interventional Cardiologist Beth Israel Deaconess Medical Center Assistant Professor of Medicine, Harvard Medical School Renal Artery Stenosis: Diagnosis and Indications for Revascularization

Harvard Medical School Clinical Clues for RAS  Onset of HTN after 55 yrs  Exacerbation of well-controlled HTN  Malignant or resistant HTN  Epigastric bruit  Unexplained azotemia  Azotemia while on ACE or ARB  Atrophic kidney or size discrepancy  Recurrent CHF or “flash” pulmonary edema  Atheroscerosis elsewhere

Harvard Medical School Making the Diagnosis of RAS: Imaging Requirements 1.Identify main and accessory renal arteries 2.Localize site of stenosis or disease 3.Provide hemodynamic significance of disease 4.Identify associated pathology

Harvard Medical School Making the Diagnosis of RAS: Imaging Options  Renal arteriography  Duplex ultrasound  MRA  CTA  Nuclear Perfusion  Renal Vein Renin Sampling

Harvard Medical School Renal Arteriography  Advantages  Meets all 4 criteria  Can size RA and intervene at the same time of diagnosis  Sensitivity and Specificity are Gold Standard  Disadvantages  Expense  Risks: Atheroembolis, CIN  Oculostenotic

Harvard Medical School Renal Arteriography Can Distinguish Integrity of Main, Accessory, and Branch Vessels  Nonatherosclerotic forms of Renovascular Disease  FMD  Misc: Spontaneous dissection, aneurysmal disease, William’s Syndrome, neurofibromatosis, trauma  Atherosclerotic Disease  Unilateral or Bilateral ostial disease (75%)  Nonostial disease (<20%)  Isolated branch disease or segmental disease (5%)

Harvard Medical School Hemodynamic Assessment  Hemodynamic Assesment confirms visual estimate  60% stenosis diameter stenosis correlates with 84% CSA reduction to create a pressure drop  Magic number is 20 mm Hg Gross, et al. Radiology : Haimovici, et al. J Cardiovasc Surg. 1962; 3:

Harvard Medical School Duplex Ultrasound  Meets 3 or 4 criteria  Least expensive  Predict whether stenting will be effective  Sensitivity 84-88%  Specificity 62-99%  Accessory arteries missed  Limited imaging in obese, gaseous patients  Technician dependent

Harvard Medical School Renal Resistive Index  Offers prognosis for intervention  Avoid Compression and Valsalva which increase RI  RI= PSV-EDV/PSV  RI=(1-[Vmin/Vmax])  Multiply by 100 Radermacher J., et al. Hypertension. 2002; 39: )

Harvard Medical School RRI: Prognosis  RI >80 is a strong predictor of death, dialysis or progressive disease  Seen with or without RAS  Found to be similar with GFR <40 and Proteinuria  However, data only based on 25 patients with RI >80 Radermacher J., et al. Hypertension. 2002; 39: )

Harvard Medical School Outcomes: 215 patients with ≥70% RAS treated with stenting  In 52% (99/191) of the patients, Cr decreased during 1-year follow-up  1.21 mg/dL (quartiles: 0.92, 1.60 mg/dL) to 1.10 mg/dL (quartiles: 0.88, 1.50 mg/dL) (P=0.047)  MAP decreased from 102±12 mm Hg (mean±SD) at baseline to 92±10 mm Hg (P<0.001)  Independent predictors of improved renal function were:  Baseline serum Cr (odds ratio [95% CI], 2.58 [1.35 to 4.94], P=0.004)  LV function (OR 1.51 [1.04 to 2.21], P=0.032) Zeller. Circulation. 2003;108:2244.

Harvard Medical School Outcomes: 215 patients with ≥70% RAS treated with stenting  Female sex, high baseline mean blood pressure, and normal renal parenchymal thickness were independent predictors for decreased mean blood pressure.  1yr mortality was approximately 7.5%  CHF or MI (73%)  Stroke (13.5%)  7 patients hospitalized with flash pulmonary edema and/or acute renal failure requiring acute hemodialysis could be withdrawn from the chronic hemodialysis program Zeller. Circulation. 2003;108:2244.

Harvard Medical School MRA of the Renals  3 of the 4 requirements  No radiation or nephrotoxins  Short duration scans  Sensitivity %  Specificity 76-94%  Expensive  Claustrophobia  May miss FMD  Overcalls Stenoses  Stent Artificact

Harvard Medical School CTA of the Renals  3 of the 4 requirements  Widely available  Visualize stents  No Flow Artifact  Short duration scans  Sensitivity %  Specificity %  Expensive  Radiation  Contrast  Claustrophobia

Harvard Medical School Indications for Continued Medical Treatment  Mild HTN  Controlled BP on Meds  Stable and Good renal function  Advanced Age  Anatomic/Technical Considerations

Harvard Medical School Indications for Renal Revascularization  Hypertensive Control  Reasonable Likelihood of Improvement  Recent escalation on top of essential HTN  Refractory, accelerated or malignant HTN  Renal Salvage  Unexplained Azotemia or ACE induced  Loss of renal mass over time  Progression of RAS  Cardiac disturbance  USA, “Flash Pulmonary Edema”, CHF

Harvard Medical School Predictors of Success  Female Gender (p=0.032)  MAP at baseline (p<0.001)  Renal Failure  More improvement if moderate dysfunction (1.5 mg/dl) vs. severe (p=0.025)  LV function normal (p=0.032)  Neutral: DM an nephrosclerosis

Harvard Medical School Case Selection: Should You ?  BP 148/94  2 Antihypertensive Meds  12 mm Hg gradient

Harvard Medical School Case Selection: Should You ?  “Drive-by Aortogram”  BP 148/94  Atenolol only  Creatinine 1.9 NO!

Harvard Medical School Case Selection: Should You ?  28 y/o nurse  BP 209/119 mm Hg  Meds: None  Creat 0.9  LRA normal YES!

Harvard Medical School Case Selection: Should You ? YES!!! BP 196/104 Prinivil, HCTZ, Metoprolol 71 mm gradient

Harvard Medical School What about the incidentalomas? Normal BP, No Meds, Normal GFR Pro  Prevent renal injury  Treat before it occludes Con  ?Data  Complications  Cost I say, No.

Harvard Medical School SummarySummary  Evaluate patient for clues suggesting RAS  Perform imaging if patient is a candidate for revascularization  Combine imaging studies if necessary  Intervene on those who have reasonable life expectancy and potential to benefit from revascularization